Therefore, strategies targeting stem cell markers (CD133), mesenchymal markers (vimentin), and cancer specific antigens (such as HER2, PSMA, ASGPR, Hepar 1, and carbamoyl phosphate synthetase 1) have been developed [197,198]. The gene discussed is PROM1; the disease is cancer.